All In Biotech

Drug Trial Radar · NCT06795048

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

A Phase IIIb/IV, Multicenter, Randomized, Open-Label, Two-Arm Study to Investigate the Efficacy, Safety, and Durability of Faricimab Administered up to Every 24 Weeks in Patients With Neovascular Age-Related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 274 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

274

Planned (sponsor's estimate)

Start

Mar 14, 2025

Primary completion

Oct 16, 2026

Study completion Sep 20, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.

Conditions

  • Neovascular Age-related Macular Degeneration (nAMD)

Interventions

  • FaricimabDrug

    Participants will receive 6-mg faricimab intravitreal (IVT) injections in the study eye according to the dosing regimen for the study arm to which they are randomized.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Best-Corrected Visual Acuity (BCVA) Score Averaged Over Weeks 44, 48, and 52Time frame: Baseline and average of Weeks 44, 48, and 52

Locations

67 sites in 12 countries. Site status is shown where the registry gives one.

  • Orange County Retina Medical Group

    Santa Ana, California

  • Florida Retina Institute

    Orlando, Florida

  • Ctr for Retina & Macular Dis

    Winter Haven, Florida

  • Retinal Vitreal Consultants

    Chicago, Illinois

  • University Retina and Macula Associates, PC

    Lemont, Illinois

  • New England Retina Consultants

    Springfield, Massachusetts

  • Sierra Eye Associates

    Sparks, Nevada

  • Retina Associates of New Jersey

    Teaneck, New Jersey

  • Vision Research Center at Eye Associates of New Mexico

    Albuquerque, New Mexico

  • Charles Retina Institute

    Germantown, Tennessee

  • Retina Consultants of Texas

    Schertz, Texas

  • Strathfield Retina Clinic

    Strathfield, New South Wales, Australia

  • Sydney Eye Hospital

    Sydney, New South Wales, Australia

  • Adelaide Eye and Retina Centre

    Adelaide, South Australia, Australia

  • Centre For Eye Research Australia

    East Melbourne, Victoria, Australia

  • Retina Specialists Victoria

    Rowville, Victoria, Australia

  • The Lions Eye Institute

    Nedlands, Western Australia, Australia

  • St. Joseph's Health Care

    London, Ontario, Canada

  • Retina Institute of Ottawa

    Ottawa, Ontario, Canada

  • Toronto Retina Institute

    Toronto, Ontario, Canada

  • Toronto Western Hospital

    Toronto, Ontario, Canada

  • Hopital du Saint Sacrement

    Québec, Quebec, Canada

  • Peking University People's Hospital

    Beijing, China

  • West China Hospital of Sichuan University

    Chengdu, China

  • Sichuan Provincial People's Hospital

    Chengdu, China

  • Zhongshan Ophthalmic Center, Sun Yat-sen University

    Guangzhou, China

  • Eye and ENT hospital, Fudan University

    Shanghai, China

  • Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech

    Wuhan, China

  • Centre Retine Gallien

    Bordeaux, France

  • Hopital Edouard Herriot - CHU Lyon

    Lyon, France

  • Centre Ophtalmologique de L'Odeon

    Paris, France

  • Hopital Lariboisiere

    Paris, France

  • Centres Ophtalmologique St Exupéry

    Saint-Cyr-sur-Loire, France

  • Clinique de l'Union

    Saint-Jean, France

  • Augenzentrum Prof. Koch GmbH

    Frankfurt, Germany

  • Medizinische Hochschule Hannover, Klinik für Augenheilkunde

    Hanover, Germany

  • Augenzentrum am St Franziskus-Hospital

    Münster, Germany

  • Universitatsklinikum Ulm, Augenklinik und Poliklinik

    Ulm, Germany

  • Universitätsklinikum Würzburg, Augenklinik und Poliklinik

    Würzburg, Germany

  • Azienda ospedaliero universitaria Policlinico Riuniti di Foggia;SC Oculistica

    Foggia, Apulia, Italy

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.